Previous Article | Next Article 
Molecular and Cellular Biology, August 2000, p. 6095-6104, Vol. 20, No. 16
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Analysis of the Complex Relationship between
Nuclear Export and Aryl Hydrocarbon Receptor-Mediated Gene
Regulation
Richard S.
Pollenz* and
E. Rick
Barbour
Department of Biochemistry and Molecular
Biology, Medical University of South Carolina, Charleston, South
Carolina
Received 10 February 2000/Returned for modification 29 March
2000/Accepted 22 May 2000
 |
ABSTRACT |
The aryl hydrocarbon receptor (AHR) contains signals for both
nuclear import and nuclear export (NES). The purpose of the studies in
this report was to determine the relationship between the nuclear
export of the AHR and AHR-mediated gene regulation. Blockage of nuclear
export in HepG2 cells with leptomycin B (LMB) resulted in increased
levels of AHR-AHR nuclear translocator (ARNT) complex in the nucleus
and correlative reductions in agonist-stimulated AHR degradation.
However, LMB exposure inhibited agonist-mediated induction of numerous
AHR-responsive reporter genes by 75 to 89% and also inhibited
induction of endogenous CYP1A1. LMB did not transform the
AHR to a ligand binding species or affect activation by TCDD
(2,3,7,8-tetrachlorodibenzo-p-dioxin). Mutagenesis of leucines 66 and 71 of the putative AHR NES resulted in a protein with
reduced function in dimerization to ARNT and binding to DNA, while
alanine substitution at leucine 69 (AHRA69) resulted in an
AHR that bound with ARNT and associated with DNA. AHRA69
protein injected directly into the nuclei of E36 cells remained nuclear following 6 h of agonist stimulation. In transient-transfection assays, AHRA69 accumulated within the nucleus was not
degraded efficiently following agonist exposure. Finally,
AHRA69 supported induction of AHR-responsive reporter genes
in an agonist-dependent manner. These findings show that it is possible
to generate an AHR protein defective in nuclear export that is
functional in agonist-mediated gene induction. This implies that the
negative effect of LMB on agonist-mediated gene induction is
independent of the nuclear export of the AHR.
 |
INTRODUCTION |
Nuclear export is an ATP-dependent
process that is essential for transport of RNA and protein from the
nucleus. The best-understood model of nuclear export proposes that a
protein containing a nuclear export signal (NES) associates with an
export receptor (the exportin or CRM-1 protein) and the complex then
exits the nucleus through the nuclear pore (6, 7, 10, 18, 19, 42,
47). The putative NES appears to be a sequence of 10 to 12 amino
acids rich in leucine (XLXXLXXLXLX), and this sequence has been shown to directly associate with CRM-1. The function of nuclear export appears to be dependent on the function of the protein containing the
NES sequence, but a theme is developing in which nuclear export functions to deliver active nuclear transcription factors to the cytoplasm for degradation. Examples of this type of mechanism include
the p53 protein where function is controlled in part through nuclear
export and subsequent degradation by cytoplasmic proteases (8, 44,
45), and the cyclin-dependent kinase p27Kip1
(40, 43, 46). The common theme in both pathways is that the
export of the effector protein from the nucleus results in reduced
levels of gene regulation since the protein is being removed from its
site of action.
Recently, it has been clearly established that the aryl hydrocarbon
receptor (AHR) protein is rapidly degraded both in vivo and in vitro
subsequent to agonist binding (11, 12, 28, 29). It has also
been shown elsewhere that the AHR contains a putative NES sequence
(36, 41). Thus, studies have been performed to establish the
relationship between the nuclear export of the AHR and protein
degradation. The studies have shown that blockage of AHR degradation
through inhibition of the 26S proteasome results in (i) increased
levels of AHR in the nucleus, (ii) increased levels of AHR-AHR nuclear
translocator (ARNT) complexes associated with DNA, and (iii) increased
levels of gene induction following exposure to
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (4). In addition, studies have shown that when nuclear export of the AHR is
blocked by the fungal antibiotic leptomycin B (LMB), the AHR is
accumulated within the nucleus following ligand binding and is not
degraded efficiently (4). Taken together, these findings
support the hypothesis that nuclear export is required for the
ligand-bound AHR to be degraded and that this type of biological
mechanism is consistent with the mechanism involved in the degradation
of p53 and p27Kip1.
The purpose of the studies detailed in this report was to further
evaluate the function of nuclear export of the AHR with focus on the
relationship between nuclear export and AHR-mediated gene regulation.
The studies show that it is possible to generate an AHR protein with
mutations in the NES that dimerizes with ARNT, binds DNA, and supports
ligand-mediated gene induction. However, the studies also demonstrate
that treatment of cells with LMB results in inhibition of AHR-mediated
gene regulation even though high levels of AHR-ARNT complex are bound
to DNA. Thus, the results indicate that there is a clear relationship
between nuclear export and AHR-mediated gene regulation but that the
relationship is complex and involves mechanisms that are directly and
indirectly related to the AHR protein.
 |
MATERIALS AND METHODS |
Chemicals.
TCDD (98% stated chemical purity) was obtained
from Radian Corp. (Austin, Tex.) and was solubilized in dimethyl
sulfoxide (Me2SO). LMB was a generous gift from M. Yoshida
(Osaka University Medical School, Osaka, Japan) and was stored as a
concentrated stock in ethanol under N2. Dextran conjugated
to Texas red was purchased from Molecular Probes.
Buffers.
Phosphate-buffered saline (PBS) is 0.8% NaCl,
0.02% KCl, 0.14% Na2HPO4, and 0.02%
K2HPO4, pH 7.4. Gel sample buffer (2×) is 125 mM Tris (pH 6.8), 4% sodium dodecyl sulfate (SDS), 25% glycerol, 4 mM
EDTA, 20 mM dithiothreitol, and 0.005% bromophenol blue. Tris-buffered
saline is 50 mM Tris and 150 mM NaCl, pH 7.5. TTBS is 50 mM Tris, 0.2%
Tween 20, and 150 mM NaCl, pH 7.5. TTBS+ is 50 mM Tris, 0.5% Tween 20, and 300 mM NaCl, pH 7.5. BLOTTO is 5% dry milk in TTBS. Lysis buffer
(2×) is 50 mM HEPES (pH 7.4), 40 mM sodium molybdate, 10 mM EGTA, 6 mM
MgCl2, and 20% glycerol. Gel shift buffer (5×) is 50 mM
HEPES (pH 7.5), 15 mM MgCl2, and 50% glycerol.
Tris-borate-EDTA (0.5×) is 45 mM Tris-borate and 1 mM EDTA.
Antibodies.
Specific antibodies against either the AHR (A-1
and A-1A) or ARNT (R-1) protein are identical to those described
previously (16, 30). All antibodies are affinity-purified
immunoglobulin G (IgG) fractions. For Western blot analysis, goat
anti-rabbit antibodies conjugated to horseradish peroxidase (GAR-HRP)
were utilized. For immunohistochemical studies, goat anti-rabbit IgG conjugated to Texas red or fluorescein isothiocyanate (FITC) was used.
Both of these reagents were purchased from Jackson Immunoresearch (West
Grove, Pa.). Polyclonal rabbit
-actin antibodies were purchased from
Sigma (St. Louis, Mo.).
Cell culture lines and growth conditions.
Wild-type
Hepa-1c1c7 (Hepa-1) and type I Hepa-1 variants were a generous gift
from James Whitlock, Jr. (Department of Pharmacology, Stanford
University). These cells were propagated in Dulbecco's minimum
essential medium supplemented with 5% fetal bovine serum (FBS). E36
cells are a Chinese hamster ovary cell line obtained from Alan Schwartz
(Washington University, St. Louis, Mo.) that has minimal levels of AHR
protein expression (4). Cells were propagated at 30°C in
minimum essential medium supplemented with 10% FBS and 4.5 g
of glucose per liter. All other cells were obtained from the American
Type Culture Collection (Manassas, Va.). HepG2 cells were propagated in
Dulbecco's minimum essential medium supplemented with 10% FBS. All
cells were passaged at 1-week intervals and used in experiments over a
2-month period. For treatment regimens, TCDD (2 nM) or LMB (5 nM) was
administered directly into growth medium for the indicated incubation
times. The vehicle used for TCDD was Me2SO at a final
concentration of 0.02%. The vehicle used for LMB was ethanol at a
final concentration of 0.1%.
Preparation of total cell lysates, cytosol, nuclear lysates, and
nuclear extracts.
Following treatment, cell monolayers were washed
twice with PBS and detached from plates by trypsinization (0.05%
trypsin-0.5 mM EDTA). Cell pellets were processed for total cell
lysates, cytosol, or total nuclear lysates essentially as detailed
previously (4, 16, 28). Nuclear extracts were prepared by
incubating isolated nuclei in MENG buffer supplemented with 400 mM KCl
as detailed previously (4, 31, 32). Protein concentrations were determined by the Coomassie Blue Plus assay (Pierce, Rockford, Ill.) with bovine serum albumin as the standard.
Quantitative Western blot analysis of AHR.
The linearity of
the AHR, ARNT, and
-actin antibodies for detection of target
proteins and the quantitative Western blotting procedure has been
detailed previously (16, 28, 29, 32, 41). Briefly, enhanced
chemiluminescence (ECL) exposures were scanned into a Power Macintosh
computer utilizing an HP Sanjet II cx/T with Adobe Photoshop 5.0 software. Images were quantified utilizing NIH Image 1.55 software. The
raw level of AHR protein was then divided by the level of
-actin
protein to generate normalized values for the concentration of the AHR
in each sample. In all studies, the trend of the data was never
affected by the normalization procedure.
Immunofluorescence staining and microscopy.
All
immunocytochemical procedures (cell plating, fixation, staining, and
photography) were carried out as previously described (4, 28, 30,
32). Cells were observed on a Zeiss Axiophot microscope using the
568-nm filter. On average, 15 to 20 fields (5 to 20 cells each) were
evaluated on each coverslip and three to four fields were photographed
to generate the raw data. Experiments were repeated at least two times.
Electrophoretic mobility shift assay (EMSA).
A
double-stranded xenobiotic response element (XRE) fragment
corresponding to the consensus XRE-1 of the CYP1A1 promoter
(39) was labeled with [32P]dCTP by Klenow
fill-in (37). Five micrograms of nuclear extract was then
incubated at 22°C for 15 min in 1× gel shift buffer supplemented with KCl (80 mM) and poly(dI-dC) (0.1 mg/ml). In some samples, 0.25 µg of affinity-purified IgG specific to AHR (1-A1) or ARNT (R-1) or
preimmune IgG was also added to samples. Approximately 4 ng of
32P-labeled XRE was then added to each sample, and the
incubation was continued for an additional 15 min at 22°C. The
samples were resolved on 5% acrylamide-0.5% Tris-borate-EDTA gels,
dried, and exposed to film.
Construction of AHR NES plasmids and eukaryotic
transfections.
All NES mutations were generated with the Quick
Change in vitro mutagenesis kit as detailed by the manufacturer
(Stratagene, Palo Alto, Calif.). The NES is located between amino acids
63 and 71 in the mouse AHR. Previous studies of this NES have used the
human sequence which is located between amino acids 64 and 71 (4,
17). The base plasmid utilized was pSportM'AHR, which contains
the full-length mouse AHR cDNA. The NES mutations are indicated in the
text. All constructs were sequenced to confirm the presence of the
mutation. For transfection studies, cells were plated into 35- or
60-mm-diameter culture dishes and incubated at 30°C for 16 to 24 h. DNA was introduced into the cell with Lipofectamine reagent as
detailed by the manufacturer (Gibco). Cells were treated with TCDD (2 nM) or Me2SO 8 to 24 h after transfection. Cells were
harvested from plates by trypsinization, and total cell lysates were
prepared as detailed above. For studies of protein localization, 5 × 105 E36 cells were plated into 60-mm-diameter culture
dishes containing poly-L-lysine-coated glass coverslips.
Cells were then transfected, treated with TCDD or vehicle, and stained
for AHR as detailed previously (4, 28, 30, 32).
In vitro protein expression, activation, and
immunoprecipitation.
Protein was produced in vitro with the TNT
coupled reticulolysate system (Promega, Madison, Wis.). In vitro
activation of the AHR was carried out for 2 h at 30°C with 10 nM
TCDD as previously detailed (4, 26, 32). Immunoprecipitation
of 35S-AHR-ARNT complexes was carried out with the
anti-AHR (A-1A) antibody following in vitro activation as previously
detailed (16, 32).
Luciferase reporter gene assay.
The reporter gene constructs
used in these studies were pGudLuc 1.1, which contains a 484-bp
fragment from the murine CYP1A1 promoter (9);
p-1897Om1A3luc, which contains an 1,897-bp fragment isolated
from the rainbow trout CYP1A3 promoter (2);
pWFG101, which contains a 2,321-bp fragment (
2296 to +25) isolated
from the mouse CYP1B1 promoter; and pMinLuc, which was
produced by ligating an oligonucleotide corresponding to the consensus
XRE-1 of the CYP1A1 promoter (39) into pGL2
(Promega). Cells were transfected with the indicated plasmids and a
constitutive
-galactosidase expression vector
(pSV-
-galactosidase) and treated with TCDD or vehicle for the times
indicated in the text. Cells were then scraped from plates in 1×
reporter gene buffer (Promega), and luciferase and
-galactosidase
activities were quantified as detailed by the manufacturer. The raw
luciferase activity was then divided by the
-galactosidase activity
to control for transfection efficiency. In all experiments, the overall
trend of the data was never changed by the normalization procedure.
Microinjection of AHR.
AHR protein was produced by the in
vitro TNT system, and expression was quantified by Western blotting.
The volume of the TNT sample was then adjusted with PBS so that the
level of expressed AHR protein was equal, and the sample was then
supplemented with 70-kDa dextran-conjugated Texas red (final
concentration of 0.25%). Equal amounts of the AHR-dextran sample were
then injected directly into the nuclei of 15 to 20 E36 cells growing on
a glass coverslip. Following the injection, the cells were immediately
treated with TCDD or Me2SO for 4 to 8 h and then fixed
and stained as detailed previously (4, 28, 30, 32).
 |
RESULTS AND DISCUSSION |
Treatment of HepG2 cells with LMB results in accumulation of
AHR-ARNT complexes in the nucleus but reduced levels of TCDD-induced
gene induction.
Previous studies have established that one
function of the AHR NES is to facilitate export of the liganded AHR
from the nucleus so that the protein can be degraded by the cytoplasmic
26S proteasome (4). Since this process removes the liganded
AHR from its site of action, it has been hypothesized that nuclear
export may play an important role in the activity of AHR-responsive
genes by controlling the level of AHR protein (4). To begin
analysis of this hypothesis, studies were initiated to evaluate whether
transcriptionally active AHR protein would be increased in the nucleus
when nuclear export was blocked by LMB. HepG2 cells were preincubated
with LMB or vehicle (ethanol) for 3 h and exposed to TCDD for an
additional 1 to 8 h, and the levels of AHR and
-actin protein
were evaluated in nuclear lysate and cytosolic fractions by Western
blotting. In the absence of LMB, TCDD treatment resulted in detectable
AHR protein in the nuclear lysate fraction between the 1- and 2-h points that declined to basal levels by 8 h (Fig.
1). This transient pattern is consistent
with the rapid degradation of the AHR observed in other cell lines
(12, 24, 28) and was directly confirmed by indirect
immunofluorescence microscopy (unpublished results). In contrast, high
levels of AHR protein were detected in the nuclear lysate fraction at
all time points when cells were pretreated with LMB for 3 h prior
to TCDD exposure (Fig. 1). Importantly, the majority of AHR protein
remained nuclear and was not redistributed to the cytoplasmic fraction
at later time points. The high level of nuclear AHR was also confirmed
by indirect immunofluorescence microscopy (unpublished results). Since
Western blot analysis does not provide information on the functionality
of the nuclear AHR, studies were performed to directly test whether the
nuclear AHR represented AHR-ARNT complexes bound to DNA.

View larger version (81K):
[in this window]
[in a new window]
|
FIG. 1.
Accumulation of AHR in the nucleus of HepG2 cells
exposed to LMB and TCDD. Duplicate plates of HepG2 cells were exposed
to ethanol (0.1%) or LMB (5 nM) for 3 h followed by TCDD (2 nM)
for an additional 1 to 6 h. Cell pellets were then solubilized in
lysis buffer, and cytosol (10 µg) and nuclear lysates (18 µg) were
resolved by SDS-PAGE. Gels were then blotted and stained with A-1A IgG
(1.0 µg/ml) and -actin IgG (1:1,000) and visualized by ECL with
GAR-HRP IgG (1:10,000). 1, 2, 4, and 6 represent hours of TCDD
exposure. M = cells exposed to Me2SO for 6 h.
|
|
HepG2 cells were preincubated with LMB or ethanol for 3 h and
exposed to TCDD for an additional 1 to 8 h, and nuclear extracts
were evaluated by EMSA. Figure
2 shows a
representative EMSA.
In control cells, AHR-ARNT complexes were detected
following 1
to 4 h of TCDD exposure but were present at greatly
reduced levels
by the 8-h point (Fig.
2, lanes 1 to 5). In contrast,
high levels
of AHR-ARNT complexes were detected at all time points when
cells
were pretreated with LMB for 3 h prior to TCDD exposure
(Fig.
2, lanes 6 to 11). To confirm that the shifted XRE detected in
the LMB-treated cells was caused by binding of AHR-ARNT complexes,
nuclear extracts were incubated with antibodies specific to AHR
or ARNT
prior to addition of the XRE oligonucleotide. The addition
of the
specific antibodies but not preimmune IgG dramatically
reduced the
observed shift (Fig.
2, lanes 11 to 14). Thus, these
results are
consistent with the Western blot data (Fig.
1) and
demonstrate that
inhibition of nuclear export by LMB results in
increased levels of
AHR-ARNT complex tightly associated with DNA
following ligand exposure.
Importantly, these results are identical
to those obtained when AHR
degradation was blocked at the level
of the 26S proteasome
(
4).

View larger version (94K):
[in this window]
[in a new window]
|
FIG. 2.
Potentiation of XRE binding activity in nuclear extracts
isolated from HepG2 cells treated with LMB and TCDD. Duplicate plates
of HepG2 cells were exposed to ethanol (0.1%) or LMB (5 nM) for 3 h followed by TCDD (2 nM) for an additional 1 to 8 h. Nuclear
extracts were prepared, and 5 µg was evaluated by EMSA. Lanes 1 and
6, 8-h exposure to Me2SO. Lanes 2, 7, and 12 to 14, 1-h
TCDD exposure. Lanes 3 and 8, 2-h TCDD exposure. Lanes 4 and 9, 4-h
TCDD exposure. Lane 10, 6-h TCDD exposure. Lanes 5 and 11, 8-h TCDD
exposure.
|
|
Having demonstrated that inhibition of nuclear export resulted in
increased levels of AHR-ARNT complexes in the nucleus, it
was pertinent
to investigate whether the increase in these complexes
would affect
AHR-mediated gene regulation. To address this issue,
HepG2 cells were
transfected with luciferase reporter constructs
containing promoter
domains isolated from the murine
CYP1A1 gene
(pGudLuc 1.1 [
9]), the murine
CYP1B1 gene (pWFG101), or
the
rainbow trout
CYP1A3 gene (p-1897
Om1A3luc
[
2]). In addition,
gene induction was evaluated with a
luciferase reporter driven
by the minimal simian virus 40 promoter and
a single XRE oligonucleotide
(pMinLuc). Following transfection, cells
were treated with LMB
or ethanol for 3 h, exposed to TCDD for an
additional 10 h, and
then assayed for luciferase activity.
Surprisingly, pretreatment
of cells with LMB markedly decreased the
TCDD-mediated luciferase
activity of all the reporter constructs by 75 to 89% (Fig.
3).
For example, the
pGudLuc 1.1 reporter, consisting of a 484-bp
fragment from the murine
CYP1A1 gene with four XREs (
9), was
induced
165-fold under control conditions but only 19-fold when
exposed to TCDD
in the presence of LMB (89% reduction in activity).
Similar levels of
inhibition were observed for the murine
CYP1B1 promoter
(81% reduction in activity), the rainbow trout
CYP1A3 promoter (79% reduction in activity), and the minimal promoter
construct as well (75% reduction in activity). Importantly, LMB
treatment had no effect on the luciferase activity of a constitutive
luciferase reporter (Fig.
3), suggesting that the reduced levels
of
reporter gene activity were not due to direct inhibition of
luciferase
activity or nuclear export of luciferase mRNA.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 3.
Inhibition of TCDD-induced reporter gene activity in
HepG2 cells exposed to LMB. HepG2 cells were cotransfected with
reporter constructs containing the indicated promoter sequences and
pSV- -galactosidase. Twenty-four hours after transfection, triplicate
plates were treated with ethanol (0.1%) or LMB (5 nM) for 3 h
followed by exposure to TCDD (2 nM) or Me2SO (0.02%) for
an additional 10 h. A set of cells were also transfected with a
constitutive luciferase reporter (pRSLV) under the control of the Rous
sarcoma virus promoter (white bars). Cells were then harvested into
reporter lysis buffer and assayed for luciferase and -galactosidase
activity. Data are expressed as the means ± standard deviations
for three samples of the normalized luciferase activity which
represents the relative luciferase units (RLU) divided by the
-galactosidase activity. Note that LMB did not affect the activity
associated with the constitutive luciferase reporter.
|
|
Since the promoter region of a reporter construct does not represent
the true context of the endogenous gene, studies were
initiated to
determine whether LMB would affect TCDD-mediated
induction of
endogenous
CYP1A1. HepG2 cells were treated with
LMB or
ethanol for 3 h and exposed to TCDD for an additional 10
h,
and total RNA was isolated. The level of
CYP1A1 mRNA was
then
determined by Northern blotting. As expected,
CYP1A1 mRNA was
induced in HepG2 cells following exposure to
TCDD (Fig.
4). However,
induction of
CYP1A1 by TCDD was strongly reduced following preincubation
of cells with LMB (Fig.
4). These results are consistent with
the data
from the reporter gene studies and suggest that some
aspect of nuclear
export is required for efficient transcription
from several
AHR-regulated promoters and at the endogenous
CYP1A1 gene.
However, it is also possible that LMB could be acting directly
at the
AHR to affect TCDD binding or the ability of TCDD to transform
the AHR
into a functional AHR-ARNT complex. To address this issue
in a
functional manner, AHR protein was produced in vitro, mixed
with ARNT,
and activated with TCDD or LMB. The formation of an
AHR-ARNT complex
was then evaluated by EMSA as detailed above.
The results show that LMB
alone does not affect the formation
of AHR-ARNT complexes and that a
fivefold excess of LMB (60 nM)
does not compete with the ability of
TCDD to transform the AHR
to a DNA binding protein (Fig.
5). Importantly, the highest
concentration
of LMB used (60 nM) was 12-fold higher than the
concentration
used in cell culture experiments (Fig.
1 to
4). Thus,
taken together
with the results of previous studies (
4),
these data add further
support to the hypothesis that the inhibitory
effect of LMB on
TCDD-mediated gene induction is the result of a block
in nuclear
export and not the interaction of LMB directly at the AHR
protein.
However, since LMB is a global inhibitor of CRM-1-mediated
export
and has numerous effects on cell function independent of the AHR
(
17,
18), it is not possible to directly determine the
relationship
between nuclear export of the AHR and AHR-mediated gene
regulation
using LMB. Thus, experiments shifted to the generation of a
functional
AHR protein that was defective in nuclear export.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 4.
Inhibition of CYP1A1 mRNA induction in HepG2
cells exposed to LMB. LMB, HepG2 cells treated with LMB (5 nM) for
13 h. LMB + TCDD, HepG2 cells treated with LMB (5 nM) for
3 h followed by exposure to TCDD (2 nM) for an additional 10 h. TCDD, HepG2 cells treated with ethanol (0.1%) for 3 h followed
by exposure to TCDD (2 nM) for an additional 10 h.
Me2SO, HepG2 cells treated with ethanol (0.1%) for 3 h followed by Me2SO (0.02%) for an additional 10 h.
After each incubation, total RNA was extracted from cells and evaluated
for CYP1A1 and -actin expression as described in
Materials and Methods. Each lane represents an independent plate of
cells. Hepa-1 = 10 µg of total RNA from murine Hepa-1 cells
treated with TCDD for 24 h.
|
|

View larger version (97K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of LMB with AHR protein. wtAHR protein
(approximately 15 ng) was expressed in vitro and mixed with an equal
amount of ARNT protein. The samples were then incubated in the presence
of TCDD (10 nM) or Me2SO (0.1%) in the presence or absence
of varying concentrations of LMB (1.2, 12, or 60 nM) or ethanol (0.1%)
for 2 h at 30°C and analyzed immediately. Equal amounts of each
sample were analyzed by EMSA with 32P-labeled XRE as
detailed in Materials and Methods. The specifically shifted AHR-ARNT
complex and free probe are indicated by the closed arrowheads. The
Western blot at the top of the EMSA represents an aliquot of the exact
sample used for the EMSA that was stained for AHR (open arrowhead).
Note that the concentration of AHR in each sample is similar. Numbers
indicate nanomolar concentrations. me, Me2SO; et,
ethanol.
|
|
Amino acid substitutions within the NES negatively affect AHR
function independent of nuclear export.
The putative NES of the
AHR is a leucine-rich sequence
(LDKLSVLRL) located between
amino acids 63 and 71 in the proximal region of the helix 2 domain of
the murine AHR. Since the helix-loop-helix is directly involved in dimerization of basic helix-loop-helix-periodicity-ARNT-single-minded protein (bHLH-PAS) proteins (1, 5, 21, 34), it was first necessary to compare several ARNT binding bHLH-PAS proteins to determine overlap between dimerization and nuclear export.
Interestingly, sequence alignment showed that five of the nine amino
acids of the NES were conserved among hypoxia factor 1
(HIF-1
),
the single-minded protein, and the nuclear PAS protein, even though
nuclear export has not been described for these proteins (Fig.
6). Importantly, only the leucine
residues that bracketed the AHR NES (positions 63 and 71) were
conserved among all the proteins, while leucine 66 was an alanine in
the other sequences and the residues that aligned with leucine 69 were
valine, isoleucine, or methionine. Therefore, leucines 66 and 69 were
selected for change, and four AHR NES mutants were produced by in vitro
mutagenesis. AHRA66 contains a leucine-to-alanine change at
amino acid 66. AHRA69 contains a leucine-to-alanine change
at amino acid 69. AHRAM contains a leucine-to-alanine
change at amino acid 66 and a leucine-to-methionine change at amino
acid 69. This amino acid change was made so that AHRAM
showed 100% identity to the HIF-1
protein from amino acids 64 to 71 (Fig. 6). Finally, AHR
NES contains
leucine-to-alanine changes at amino acids 69 and 71.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 6.
Alignment of HLH regions of bHLH-PAS proteins. The HLH
regions for the mouse HIF-1 , single-minded protein, nuclear PAS,
AHR, and ARNT proteins were analyzed by Lasergene software (DNASTAR
Inc., Madison, Wis.). The helix 1, loop, and helix 2 regions are shown.
The putative NES within helix 2 of AHR is underlined. Conserved leucine
residues with the AHR NES are indicated. SEQ., sequence.
|
|
To assess the function of the various NES mutants, wild-type AHR
(wtAHR), AHR
A66, AHR
A69, AHR
AM, and
AHR
NES proteins
were expressed in vitro and quantified
by Western blotting. Equal
amounts of each AHR were then mixed with an
equal amount of ARNT
protein, and the sample was incubated in the
presence of TCDD
or Me
2SO for 2 h at 30°C. The
formation of AHR-ARNT complexes
was then evaluated by EMSA. Figure
7A shows that all the AHR NES
mutants
exhibited some level of TCDD-dependent binding to the
XRE compared to
the wtAHR protein. However, AHR
NES bound
at only 18% of
the level of wtAHR, while AHR
A66 and AHR
AM
bound
at approximately 50% of the level of wtAHR. In contrast, the
AHR
A69 protein functioned at approximately 92% of the
level of the wtAHR
in the context of the in vitro EMSA. To further
assess the binding
of AHR
A69, EMSA studies were repeated
with varying levels of in
vitro-activated wtAHR and AHR
A69
proteins. Analysis of the shifted
XRE showed that both wtAHR and
AHR
A69 produced similar levels
of shifted XRE at all
concentrations, and the compiled data showed
an identical slope over
the concentration range used (R. S. Pollenz,
unpublished data).
Thus, the A69 mutation does not appear to affect
the activation or DNA
binding of the AHR and the protein functions
at the same level as the
wtAHR.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 7.
Functional analysis of mutations within the NES of the
AHR. The indicated AHR protein was expressed in vitro and mixed with an
equal amount of cold or 35S-labeled ARNT protein
(approximately 15 ng). The samples were then incubated in the presence
of TCDD (10 nM) or Me2SO (0.1%) for 2 h at 30°C and
analyzed immediately. (A) Equal amounts of each sample were analyzed by
EMSA with 32P-labeled XRE as detailed in Materials and
Methods. The specifically shifted AHR-ARNT complex and free probe are
indicated by the closed arrowheads. The Western blot at the top of the
EMSA represents an aliquot of the exact sample used for the EMSA that
was stained for AHR (open arrowhead). Note that the concentration of
AHR in each sample is similar. (B) Equal amounts of each sample were
precipitated with anti-AHR IgG (A-1A) or preimmune IgG and resolved by
SDS-PAGE. Specificity is demonstrated by the lack of
35S-labeled ARNT in samples precipitated with preimmune
IgG. (C) The Western blot shown represents an aliquot of the exact AHR
sample used for the immunoprecipitation that was stained for AHR (open
arrowhead). Note that the concentration of AHR in each sample is
similar.
|
|
To better understand why the AHR
NES exhibited reduced
activity in the in vitro activation assay,
immunoprecipitation
studies were carried out. Equal amounts of
wtAHR, AHR
NES,
and AHR
A69 were mixed
with
35S-labeled ARNT and activated with TCDD or
Me
2SO for 2 h at 30°C.
The samples were then
immunoprecipitated with IgG against AHR
(A-1A) and protein A-Sepharose,
and the pelleted material was
resolved by SDS-polyacrylamide gel
electrophoresis (PAGE). The
results show that wtAHR and
AHR
A69 associate with
35S-labeled ARNT in a
TCDD-dependent manner, while samples containing
AHR
NES
do not appear to associate with ARNT to a significant
degree (Fig.
7B).
Thus, the reduced level of DNA binding observed
in the gel shift assay
(Fig.
7A) is explained by the reduced level
of dimerization of
AHR
NES and is consistent with a mutation
of the
conserved leucine at position 71. Collectively, these results
show that
the AHR
A69 protein exhibits TCDD-dependent function
at the
level of dimerization and DNA binding in vitro. However,
substitutions
at residue 66 or 71 appear to negatively affect
AHR function at the
level of dimerization and DNA binding that
is independent of any
nuclear export
function.
AHRA69 is defective in nuclear export and is not
degraded efficiently.
It was next necessary to determine whether
the AHRA69 protein was defective in nuclear export. In the
first set of studies, a microinjection strategy was utilized. First,
wtAHR and AHRA69 proteins were produced in vitro and
evaluated by Western blotting to ensure that equal levels were
expressed (Fig. 8, bottom panel). The AHR
was then mixed with 70-kDa dextran-conjugated Texas red (0.5% final
concentration) and microinjected directly into the nuclei of E36 cells.
Following microinjection, cells were treated with either TCDD or
Me2SO for 6 h and then fixed and stained for AHR which
was visualized with goat anti-rabbit-FITC. The dextran-Texas red
conjugate serves as a control to identify those cells that were
injected and as a marker of nuclear integrity since 70-kDa dextran is
too large to freely diffuse through the nuclear pore complex. The
results show that specific staining for the AHR is observed only in the
nuclei of cells that exhibit concomitant Texas red fluorescence (Fig.
8A, B, and E to H, white arrowheads). However, when cells containing
wtAHR were exposed to TCDD for 6 h, there was a dramatic reduction
in AHR immunoreactivity compared to that for Me2SO-treated
cells (Fig. 8, compare panels A and C). Importantly, while wtAHR
immunofluorescence was reduced following TCDD treatment, Texas red
fluorescence remained essentially unchanged, illustrating that
reductions were not related to a loss of nuclear integrity. In
contrast, high levels of AHRA69 were observed in the nuclei
of TCDD-treated cells and the staining intensity remained similar to
that observed for cells treated with Me2SO (Fig. 8, compare
panel G to panels A and E). Collectively, these results suggest that
the AHRA69 is not efficiently exported from the nucleus and
thus is not readily degraded following TCDD exposure. These findings
are in agreement with previous studies that have established that the
liganded AHR is rapidly degraded in the cytoplasm following nuclear
export (4, 28) and support a hypothesis that
AHRA69 is defective in nuclear export.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 8.
Distribution of wtAHR and AHRA69 protein
injected into E36 cells. wtAHR and AHRA69 proteins were
expressed in vitro and mixed with 70-kDa dextran-conjugated Texas red.
The samples were then injected into the nuclei of E36 cells and exposed
to TCDD (2 nM) or Me2SO (0.02%) for 6 h at 30°C.
Following the incubation, cells were fixed and stained with 1 µg of
A-1 IgG per ml followed by goat anti-rabbit-FITC (1:500). Identical
fields showing FITC fluorescence (A, C, E, and G) and Texas red
fluorescence (B, D, F, and H) are shown. (A and B) Cells injected with
wtAHR and exposed to Me2SO. (C and D) Cells injected with
wtAHR and exposed to TCDD. (E and F) Cells injected with
AHRA69 and exposed to Me2SO. (G and H) Cells
injected with AHRA69 and exposed to TCDD. Arrowheads
indicate the nuclei injected with AHR protein. The Western blot shown
at the bottom represents an aliquot of the exact wtAHR and
AHRA69 proteins used for the microinjection that were
stained for AHR (open arrows).
|
|
To directly quantify the TCDD-induced degradation of
AHR
A69, expression vectors containing wtAHR or
AHR
A69 were transfected
into E36 cells. Ten hours after
transfection, cells were exposed
to TCDD or Me
2SO for
16 h and either lysed to produce total cell
lysates or fixed and
stained for AHR to evaluate subcellular distribution.
Figure
9 shows a representative Western blot
stained for AHR and

-actin. In mock-transfected cells, there is
little detectable
AHR, while cells expressing wtAHR and
AHR
A69 express a protein
that migrates at approximately 95 kDa. When the transfected cells
were treated with TCDD for 16 h,
wtAHR was reduced by 55% compared
to the level for
Me
2SO-treated cells. In contrast, AHR
A69
protein
was depleted by only 22% compared to the level in
Me
2SO-treated
cells following 16 h of exposure (Fig.
9). These findings support
the results of the microinjection studies
and are consistent with
the observation that the AHR
A69 is
not degraded efficiently. To
correlate these results with the
subcellular location of wtAHR
or AHR
A69, transfected cells
were fixed and stained. Representative
fields of cells are presented in
Fig.
10. The wtAHR or
AHR
A69 protein
was highly expressed in transfected cells
and exhibited a predominately
cytoplasmic pattern of fluorescence when
treated with Me
2SO (Fig.
10A to C and G to I). The
specificity of the A-1 antibody is demonstrated
by the lack of staining
in nontransfected cells. When cells expressing
wtAHR were treated with
TCDD for 24 h, there was a general reduction
in the fluorescence
intensity, but the overall staining pattern
remained predominately
cytoplasmic with modest accumulation of
AHR in the nuclear compartment
(Fig.
10D to F). In contrast, cells
expressing the AHR
A69
protein showed markedly increased levels
of AHR staining in the nucleus
following 24 h of TCDD exposure
and exhibited low to moderate
levels of cytoplasmic fluorescence
(Fig.
9J to L). Taken together with
the results of the microinjection
studies (Fig.
8), these data provide
further evidence that the
putative NES present in the AHR has reduced
function when leucine
69 is changed to an alanine and that blockage of
nuclear export
at the level of the AHR inhibits ligand-mediated
degradation of
the AHR protein.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 9.
Western blot analysis of recombinant AHR protein
expression in E36 cells exposed to TCDD. E36 cells were transfected
with expression vectors for wtAHR or AHRA69. Triplicate
plates were exposed to TCDD (2 nM) or Me2SO (0.02%) for
16 h, and 18 µg of total cell lysate was resolved by SDS-PAGE.
Blots were stained with A-1A IgG (1.0 µg/ml) and -actin IgG
(1:1,000) and visualized by ECL with GAR-HRP IgG (1:10,000). Bands were
quantified and normalized as detailed previously (14, 17, 19, 23,
25). Data are expressed as the percentages of wtAHR or
AHRA69 protein compared to that for Me2SO
(DMSO)-treated controls. Bars represent the averages ± standard
errors of three independent samples.
|
|

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 10.
Subcellular localization of recombinant AHR protein
expression in E36 cells exposed to TCDD. All slips were incubated with
A-1 IgG (1.0 µg/ml) and visualized with goat anti-rabbit-Texas red
IgG (1:750). (A to C) E36 cells expressing wtAHR and stained for AHR
following a 24-h exposure to Me2SO (0.02%). (D to F) E36
cells expressing wtAHR and stained for AHR following a 24-h exposure to
TCDD (2 nM). (G to I) E36 cells expressing AHRA69 and
stained for AHR following a 24-h exposure to Me2SO
(0.02%). (J to L) E36 cells expressing AHRA69 and stained
for AHR following a 24-h exposure to TCDD (2 nM). All panels were
photographed and printed for identical times. Note the greatly reduced
AHR reactivity in untransfected cells. Bar = 10 µm.
|
|
TCDD-mediated gene induction is not inhibited in cells expressing
an AHR defective in nuclear export.
The previous studies have
demonstrated that the AHRA69 (i) accumulates in the nucleus
in a ligand-dependent manner, (ii) is capable of forming a functional
dimer with ARNT protein, (iii) associates with putative XRE
oligonucleotides in vitro, and (iv) is not efficiently exported
from the nucleus following ligand exposure. Thus, the final set
of studies focused on whether AHRA69 could support
TCDD-mediated induction of CYP1A1. To address this issue, expression vectors containing wtAHR, AHRA69,
AHRAM, or AHR
NES were cotransfected
into the type I Hepa-1 or E36 cell line along with the TCDD-responsive
pGudLuc 1.1 luciferase reporter and a constitutive
-galactosidase
construct. Similar to the E36 cell line, type I cells have reduced
levels of AHR protein and show minimal levels of TCDD-inducible gene
induction (24, 48). Ten hours after transfection, cells were
exposed to TCDD or Me2SO for 16 h and either processed
for total cell lysates or analyzed for the level of luciferase and
-galactosidase activity. A representative experiment for the type I
cells is shown in Fig. 11A. Type I
cells transfected with only pGudLuc 1.1 exhibited low levels of
constitutive reporter gene activity that were induced approximately
21-fold following exposure to TCDD. When wtAHR was expressed in the
type I cells, however, the basal luciferase activity increased 25-fold above background and was induced an additional 7-fold following TCDD
exposure. The increased level of basal luciferase activity in the
absence of exogenous ligand was consistent with numerous other reports
that have utilized reporter genes to assess AHR function and likely
reflects the high level of AHR or ARNT protein that is expressed in the
transfected cells (14, 20, 22, 23). Importantly,
AHRA69 and AHRAM also showed increased levels of basal luciferase activity in the absence of exogenous ligand but
were induced an additional 7- to 13-fold following addition of TCDD. In
contrast, the cells expressing the AHR
NES did not show
increased levels of luciferase activity above background and also did
not support induction of luciferase above the level induced by the
endogenous AHR (Fig. 11A). These results are consistent with the
reduced ability of AHR
NES to dimerize with ARNT and bind
DNA. To confirm that exogenous AHR protein was expressed in the
transfected cells, Western blot analysis was performed on plates of
cells that were transfected with the identical DNA solutions used to
generate the data in Fig. 11A. The results show that the level of AHR
in each population is increased above the endogenous level found in
cells transfected with parental vector alone. Importantly, the high
level of expression of AHR
NES indicates that the reduced
functionality of this protein is not due to reduced expression. The
lower level of AHRA69 and AHRAM protein than of
wtAHR was consistent with a reduced level of transfection efficiency as
determined by analysis of
-galactosidase activity.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 11.
Induction of TCDD-induced reporter gene activity in
cells expressing AHRA69. Type I Hepa-1 E36 CHO cells were
cotransfected with pGudLuc 1.1, pSV- -galactosidase, and pSport
expression vectors containing wtAHR, AHRA69,
AHRAM, or AHR NES. Control plates of cells
were transfected with pGudLuc 1.1, pSV- -galactosidase, and pSport
(no AHR). Eight hours after transfection, triplicate plates of cells
were treated with TCDD (2 nM) or Me2SO (0.02%) for 16 h. (A) Type I cells were harvested into reporter lysis buffer and
assayed for luciferase and -galactosidase activity. Data are
expressed as the means ± standard deviations for three samples of
normalized luciferase activity which represents the relative luciferase
units (RLU) divided by the -galactosidase activity. (B) Western blot
analysis of total cell lysates from plates of type I cells transfected
with the identical DNA solutions used for panel A. Blots were stained
with A-1A IgG and -actin IgG as detailed in the text. (C) E36 cells
were harvested into reporter lysis buffer and assayed for luciferase
and -galactosidase activity. Data are expressed as the means ± standard deviations for three samples of normalized luciferase activity
which represents the relative luciferase units (RLU) divided by the
-galactosidase activity. Shown are results of Western blot analysis
of total cell lysates from representative plates of E36 cells
transfected with the identical DNA solutions used to generate the
luciferase data. Blots were stained with A-1A IgG as detailed in the
text.
|
|
In the E36 cells, the expression of both wtAHR and AHR
A69
increased luciferase activity above basal levels as observed in
the
type I studies and also induced increased levels of luciferase
in the
presence of TCDD (Fig.
11C). Interestingly, the overall
level of
induction above basal activity was not as high as that
observed in the
type I cells (1.5- to 2.5-fold), and the AHR
A69 was able to
induce activity to a slightly higher level than was
wtAHR. These
findings may be the result of a higher level of AHR
expression in the
transfected E36 cells or reduced levels of endogenous
AHR protein. To
confirm the expression of the AHR, Western blot
analysis was carried
out on representative cell lysates produced
from cells transfected with
the identical DNA samples used to
produce the luciferase data. In all
samples, AHR was expressed
with the wtAHR showing a 50% reduction in
concentration following
TCDD exposure while the AHR
A69
remained at a level similar to
that in Me
2SO-treated cells
(as shown in Fig.
9). Collectively,
the results of these experiments
indicate that the AHR
A69 protein
functions in AHR-mediated
gene induction. Thus, the inhibition
of nuclear export directly at the
level of the AHR is not a component
of the inhibition of gene induction
observed when cells are exposed
to
LMB.
Conclusions and implications.
Currently, there are several
signaling cascades that define a novel biological theme in which the
interplay between nuclear export and protein degradation plays a major
role in determining the magnitude and duration of gene regulation. For
example, the level of p53 protein is controlled in part by nuclear
export and subsequent degradation by cytoplasmic proteases (8, 14,
44, 45). If nuclear export of p53 is inhibited, there is a
general upregulation of p53-dependent genes (8, 37). Another
pathway involves p27Kip1, p27Kip1 is a
cyclin-dependent kinase that arrests cells in G1
(40) and appears to be reduced in certain types of cancer
(43). Importantly, the level of p27Kip1 is
controlled in part through nuclear export following association with
p38 (JAB1), a protein that contains an NES and allows export of
p27Kip1 to the cytoplasm for degradation (27,
46). The common theme in both pathways is that the export of the
effector protein from the nucleus results in reduced levels of gene
regulation since the protein is being removed from its site of action.
The studies presented in this report show that nuclear export and
protein degradation are essential components of the AHR-mediated signal transduction pathway as well.
Interestingly, the relationship between nuclear export and AHR-mediated
gene regulation appears to involve the AHR directly
and indirectly. In
the first instance, the presence of the NES
within the AHR sequence
appears to be directly related to the
transport of the AHR from the
nucleus so that the protein is degraded
by the cytoplasmic proteasome
(
4). Since the result of nuclear
export is an actual
reduction in the level of transcriptionally
active AHR protein, proper
functioning of nuclear export and the
proteolytic machinery likely
serves to control the magnitude and
duration of gene induction or
repression by the AHR-ARNT complex.
This view is supported by the
observation that ligand exposure
results in rapid reductions in the
level of AHR protein and AHR-ARNT
complexes in vivo and in vitro
(
28,
29,
31,
33,
36,
41) and the finding that mutations
within the AHR NES or direct
inhibition of the cytoplasmic proteasome
results in reduced degradation
of the AHR, high levels of nuclear AHR,
and high levels of AHR-mediated
gene induction (
4). Thus,
the direct role of nuclear export
would be similar to that observed for
the p53 and p27
Kip1 pathways (
8,
40,
43-46) and
would involve attenuation of
AHR-mediated gene induction when the
pathway is functioning properly.
Alternatively, a recent report
suggests that the AHR protein is
rapidly degraded once it enters the
nuclear compartment regardless
of ligand exposure, dimerization with
ARNT, or the presence of
hsp90 (
35). While compelling, this
hypothesis is not supported
by any of the previous (
4,
15)
or current studies from this
lab where high levels of the endogenous
AHR protein have been
shown to accumulate in the nucleus and exhibit
reduced levels
of degradation. It must be noted, though, that
comparisons of
the results of Robert and Whitelaw (
35) to
studies that have
evaluated endogenous AHR protein are difficult
because Robert
and Whitelaw (
35) analyzed a stable cell line
expressing a modified
form of the AHR (DRNLS) that is likely
functioning in an aberrant
manner compared to wtAHR protein (which was
not tested in the
studies). For example, it is intriguing that the
kinetics of DRNLS
degradation were not affected by the presence of AHR
ligands,
hsp90, or ARNT (
35). Such findings call into
question the physiological
significance of the DRNLS model for studying
AHR proteolysis,
since it is clear that the endogenous AHR can be
translocated
to the nucleus in the presence of hsp90 and is protected
from
degradation (
4,
15). Thus, while it cannot be ruled out
that
some level of ligand-bound AHR might be degraded by a nuclear
protease in certain cells or tissues, the current data overwhelmingly
support a model in which AHR is degraded in the cytoplasm by the
26S
proteasome following ligand binding, nuclear import, and nuclear
export
(references
4 and
15 and present
studies).
While the function of the AHR NES correlates well with ligand-mediated
degradation of the AHR (
4), an explanation for the
inhibition of AHR-mediated gene induction following exposure of
cells
to LMB is less clear. The data suggest that a nuclear export-dependent
process is also important in AHR-mediated signaling but that it
is
independent of the nuclear export of the AHR. This view is
supported by
the following observations. First, the AHR is accumulated
in the
nucleus following LMB exposure and appears to be associated
with ARNT
in a complex bound to DNA. Second, inhibition of AHR
degradation by
proteasome inhibitors results in high levels of
accumulation of
AHR-ARNT in the nucleus that have a positive impact
on AHR-mediated
gene regulation (
4). Finally, direct mutation
of the AHR NES
does not have a negative impact on AHR-mediated
gene regulation even
though the AHR appears to accumulate in the
nucleus just as if export
is blocked by the use of LMB. Thus,
these results are consistent with
the presence of an additional
negatively acting factor that may or may
not associate with AHR
and/or
ARNT.
There are currently a number of reports that have characterized
proteins that act negatively on AHR-mediated signaling. These
include a
dominant-negative ARNT isoform identified in rainbow
trout (
26,
32), a factor that associates with ARNT in human
fibroblasts
(
13), and an AHR repressor protein termed AHRR that
has the
ability to bind ARNT and DNA without inducing genes (
25).
Thus, there is growing evidence that negative regulators are involved
in AHR-mediated signaling. Interestingly, the AHRR appears to
be the
product of an AHR-inducible gene, and the protein itself
shares
homology to the AHR within the bHLH region (
25). Indeed,
amino acid sequence analysis of the AHRR indicates that the protein
contains a putative NES within the helix 2 domain that is identical
to
that of the AHR
(K
LDK
LSV
LR
LS).
While the
presence of the NES does not prove that it is functional
in the AHRR,
it is compelling to hypothesize that the AHRR or
a similar factor
containing an NES may be responsible for the
inhibitory results
obtained with LMB. Studies are currently under
way to explore these
possibilities and further assess the consequences
for AHR-mediated gene
regulation when nuclear export is
inhibited.
 |
ACKNOWLEDGMENTS |
Several individuals deserve special thanks for their input in the
project. We acknowledge the contribution of Steve Frawley and Bill
Faught, who carried out the microinjections; William Greenlee, who
provided the CYP1B1 reporter construct and shared unpublished data with
the laboratory; Michael Carvan, who provided the rtCYP1A3 reporter
construct; Michael Denison, who provided the minimal XRE construct;
Chris Bradfield, for the original pSportM'AHR vector; Minoru Yoshida,
who generously donated LMB; Brian Necela, who carried out the
immunoprecipitation studies; and Alan Schwartz, for providing the E36
cell line and also offering his insights into protein degradation.
Finally, we thank Nikos Davarinos for his participation in aspects of
this project and Michael Kern for his support and helpful discussions
of the work. The reviewers of this work are also acknowledged for their
critical insights with regard to the work.
This work was supported in part by National Institutes of Health grants
ES-08980 and ES-10401 to R.S.P., and by Institutional Research Funds to
the Medical University of South Carolina for 1999-2000.
 |
FOOTNOTES |
*
Corresponding author. Present address: Department of
Biology, University of South Florida, 4204 E. Fowler Ave., SCA 110, Tampa, FL 33620-5200. Phone: (813) 974-3250. Fax: (813) 974-3263. E-mail: rpollen{at}chuma.cas.usf.edu.
 |
REFERENCES |
| 1.
|
Basci, S. G., and O. Hankinson.
1996.
Functional characterization of DNA binding domains of the heterodimeric AHR complex imputing canonical bHLH protein-DNA interactions.
J. Biol. Chem.
271:8843-8850[Abstract/Free Full Text].
|
| 2.
|
Carvan, M. J.,
L. V. Ponomareva,
W. A. Solis,
R. S. Matlib,
A. Puga, and D. W. Nebert.
1999.
Trout CYP1A3 gene: recognition of fish DNA motifs by mouse regulatory proteins.
Mar. Biotechnol.
1:155-166[CrossRef][Medline].
|
| 3.
|
Chang, C.-Y., and A. Puga.
1998.
Constitutive activation of the aromatic hydrocarbon receptor.
Mol. Cell. Biol.
18:525-535[Abstract/Free Full Text].
|
| 4.
|
Davarinos, N. A., and R. S. Pollenz.
1999.
Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded via the cytoplasmic proteasome following nuclear export.
J. Biol. Chem.
274:28707-28715.
|
| 5.
|
Dolwick, K. M.,
H. I. Swanson, and C. A. Bradfield.
1993.
In vitro analysis of Ah receptor domains involved in ligand-activated DNA recognition.
Proc. Natl. Acad. Sci. USA
90:8566-8570[Abstract/Free Full Text].
|
| 6.
|
Fornerod, M.,
J. van Deursen,
S. van Baal,
A. Reynolds,
D. Davis,
K. G. Murti,
J. Fransen, and G. Grosveld.
1997.
The human homologue of yeast CRM1 is a dynamic subcomplex with Can/nup214 and a novel nuclear pore component Nup 88.
EMBO J.
16:807-816[CrossRef][Medline].
|
| 7.
|
Fornerod, M.,
M. Ohno,
M. Yoshida, and I. A. Mattaj.
1997.
CRM1 is an export receptor for leucine-rich nuclear export signals.
Cell
90:1051-1060[CrossRef][Medline].
|
| 8.
|
Freedman, D. H., and A. J. Levine.
1998.
Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus.
Mol. Cell. Biol.
18:7288-7293[Abstract/Free Full Text].
|
| 9.
|
Garrison, P. M.,
K. Tullis,
J. M. Aarts,
A. Brouwer,
J. P. Giesy, and M. S. Denison.
1996.
Species specific recombinant cell lines as bioassay systems for the detection of TCDD-like chemicals.
Fundam. Appl. Toxicol.
30:194-203[CrossRef][Medline].
|
| 10.
|
Gerace, L.
1995.
Nuclear export signals and the fast track to the cytoplasm.
Cell
82:341-344[CrossRef][Medline].
|
| 11.
|
Giannone, J.,
W. Li,
M. Probst, and A. Okey.
1998.
Prolonged depletion of AH receptor without alteration of receptor mRNA levels after treatment of cells in culture with 2,3,7,8-tetrachloro-dibenzo-p-dioxin.
Biochem. Pharmacol.
55:489-497[CrossRef][Medline].
|
| 12.
|
Giannone, J. V.,
A. B. Okey, and P. A. Harper.
1995.
Characterization of polyclonal antibodies to the aromatic hydrocarbon receptor.
Can. J. Physiol. Pharmacol.
73:7-17[Medline].
|
| 13.
|
Gradin, K.,
R. Toftgard,
L. Poellinger, and A. Berghard.
1999.
Repression of dioxin signal transduction in fibroblasts.
J. Biol. Chem.
274:13511-13518[Abstract/Free Full Text].
|
| 14.
|
Haupt, Y.,
R. Maya,
A. Kazaz, and M. Oren.
1997.
Mdm2 promotes the rapid degradation of p53.
Nature
387:296-299[CrossRef][Medline].
|
| 15.
|
Heid, S. E.,
R. S. Pollenz, and H. I. Swanson.
2000.
Role of heat shock protein 90 in mediating agonist-induced activation of the aryl hydrocarbon receptor.
Mol. Pharmacol.
57:82-92[Abstract/Free Full Text].
|
| 16.
|
Holmes, J. L., and R. S. Pollenz.
1997.
Determination of ARNT protein concentration and subcellular localization in hepatic and non-hepatic cell culture line.
Mol. Pharmacol.
52:202-211[Abstract/Free Full Text].
|
| 17.
|
Ikuta, T.,
H. Eguchi,
T. Tachibana,
Y. Yoneda, and K. Kawajiri.
1998.
Nuclear localization and export signals of the human aryl hydrocarbon receptor.
J. Biol. Chem.
273:2895-2904[Abstract/Free Full Text].
|
| 18.
|
Kudo, N.,
B. Wolff,
T. Sekimoto,
E. Schreiner,
Y. Yoneda,
M. Yanagida,
S. Horinouchi, and M. Yoshida.
1998.
Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1.
Exp. Cell Res.
242:540-547[CrossRef][Medline].
|
| 19.
|
Kudo, N.,
S. Khochbin,
K. Nishi,
K. Kitano,
M. Yanagida,
M. Yoshida, and S. Horinouchi.
1997.
Molecular cloning and cell cycle-dependent expression of mammalian CRM-1, a protein involved in nuclear export of proteins.
J. Biol. Chem.
272:29742-29751[Abstract/Free Full Text].
|
| 20.
|
Li, H.,
L. Dong, and J. P. Whitlock.
1994.
Transcriptional activation function of the ARNT protein.
J. Biol. Chem.
269:28098-28105[Abstract/Free Full Text].
|
| 21.
|
Lindebro, M. C.,
L. Poellinger, and M. L. Whitelaw.
1995.
Protein-protein interactions via PAS domains: role of the PAS domain in positive and negative regulation of the bHLH/PAS dioxin receptor-ARNT transcription factor complex.
EMBO J.
14:3528-3539[Medline].
|
| 22.
|
Mason, G. G. F.,
A.-M. Witte,
M. L. Whitelaw,
C. Antonsson,
J. McGuire,
A. Wilhelmsson,
L. Poellinger, and J.-K. Gustafsson.
1994.
Purification of the DNA binding form of dioxin receptor. Role of the Arnt cofactor in regulation of dioxin receptor function.
J. Biol. Chem.
269:4438-4449[Abstract/Free Full Text].
|
| 23.
|
Matsushita, N.,
K. Sogawa,
M. Ema,
A. Yoshida, and Y. Fujii-Kuriyama.
1993.
A factor binding to the xenobiotic responsive element (XRE) of P-4501A1 gene consists of at least two helix-loop-helix proteins, Ah receptor and Arnt.
J. Biol. Chem.
268:21002-21006[Abstract/Free Full Text].
|
| 24.
|
Miller, A. G.,
D. Isreal, and J. P. Whitlock.
1983.
Biochemical and genetic analysis of variant mouse hepatoma cells defective in the induction of benzo(a)pyrene-metabolizing enzyme activity.
J. Biol. Chem.
258:3523-3527[Abstract/Free Full Text].
|
| 25.
|
Mimura, J.,
M. Ema,
K. Sogawa, and Y. Fujii-Kuriyama.
1999.
Identification of a novel mechanism of regulation of Ah (dioxin) receptor function.
Genes Dev.
13:20-25[Abstract/Free Full Text].
|
| 26.
|
Necela, B., and R. S. Pollenz.
1999.
Functional analysis of activation and repression domains with the rainbow trout ARNT protein.
Biochem. Pharmacol.
57:1177-1190[CrossRef][Medline].
|
| 27.
|
Pagano, M.,
S. W. Tam,
A. M. Theodoras,
P. Beer-Romero,
G. Del Sal,
V. Chau,
P. R. Yew,
G. F. Draetta, and M. Rolfe.
1995.
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.
Science
269:682-685[Abstract/Free Full Text].
|
| 28.
|
Pollenz, R. S.
1996.
The Ah-receptor but not the Arnt protein is rapidly depleted in hepatic and non-hepatic culture cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Mol. Pharmacol.
49:391-398[Abstract].
|
| 29.
|
Pollenz, R. S.,
M. J. Santostefano,
E. Klett,
V. M. Richardson,
B. Necela, and L. S. Birnbaum.
1998.
A single oral dose of TCDD results in sustained depletion of AHR protein in female Sprague-Dawley rats.
Toxicol. Sci.
42:117-128[Abstract/Free Full Text].
|
| 30.
|
Pollenz, R. S.,
C. A. Sattler, and A. Poland.
1994.
The aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator protein show distinct subcellular localizations in Hepa 1c1c7 cells by immunofluorescence microscopy.
Mol. Pharmacol.
45:428-438[Abstract].
|
| 31.
|
Pollenz, R. S., and B. Necela.
1998.
Characterization of two continuous cell lines from Oncorhynchus mykiss for models of AHR-mediated signal-transduction.
Aquat. Toxicol.
41:31-49[CrossRef].
|
| 32.
|
Pollenz, R. S.,
H. R. Sullivan,
J. Holmes,
B. Necela, and R. E. Peterson.
1996.
Isolation and expression of cDNAs from rainbow trout that encode two novel bHLH/PAS proteins with distinct functions in the presence of the aryl hydrocarbon receptor.
J. Biol. Chem.
271:30886-30896[Abstract/Free Full Text].
|
| 33.
|
Reick, M.,
R. W. Robertson,
D. S. Pasco, and J. B. Fagan.
1994.
Down-regulation of nuclear aryl hydrocarbon receptor DNA-binding and transactivation functions.
Mol. Cell. Biol.
14:5653-5660[Abstract/Free Full Text].
|
| 34.
|
Reisz-Porszasz, S.,
M. R. Probst,
B. N. Fukunaga, and O. Hankinson.
1994.
Identification of functional domains of the aryl hydrocarbon receptor nuclear translocator protein (ARNT).
Mol. Cell. Biol.
14:6075-6086[Abstract/Free Full Text].
|
| 35.
|
Roberts, B. J., and M. L. Whitelaw.
1999.
Degradation of the basic-helix-loop-helix/Per-ARNT-Sim homology domain dioxin receptor via the ubiquitin/proteasome pathway.
J. Biol. Chem.
274:36351-36356[Abstract/Free Full Text].
|
| 36.
|
Roman, B. L.,
R. S. Pollenz, and R. E. Peterson.
1998.
AHR and ARNT expression and CYP1A1 induction in the adult male rat reproductive tract.
Toxicol. Appl. Pharmacol.
150:228-239[CrossRef][Medline].
|
| 37.
|
Roth, J.,
M. Dobbelstein,
D. A. Freedman,
T. Shenk, and A. J. Levine.
1998.
Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of p53 protein via a pathway used by the human immunodeficiency virus rev protein.
EMBO J.
17:554-564[CrossRef][Medline].
|
| 38.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 39.
|
Shen, E. S., and J. P. Whitlock, Jr.
1992.
Protein-DNA interactions at the dioxin responsive enhancer.
J. Biol. Chem.
267:6815-6819[Abstract/Free Full Text].
|
| 40.
|
Sherr, C. J.
1996.
Cancer cell cycles.
Science
274:1672-1677[Abstract/Free Full Text].
|
| 41.
|
Sommer, R. J.,
K. Sojka,
R. S. Pollenz,
P. Cooke, and R. E. Peterson.
1999.
AHR and ARNT protein and mRNA concentrations in rat prostate: effects of stage of development and TCDD.
Toxicol. Appl. Pharmacol.
155:177-189[CrossRef][Medline].
|
| 42.
|
Stade, K.,
C. S. Ford,
C. Guthrie, and K. Weis.
1997.
Exportin 1 (CRM1) is an essential nuclear export factor.
Cell
90:1041-1050[CrossRef][Medline].
|
| 43.
|
Steeg, P. S., and J. S. Abrams.
1997.
Cancer prognostics: past, present and p27.
Nat. Med.
3:152-154[CrossRef][Medline].
|
| 44.
|
Tao, W., and A. J. Levine.
1999.
P19ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.
Proc. Natl. Acad. Sci. USA
96:6937-6941[Abstract/Free Full Text].
|
| 45.
|
Tao, W., and A. J. Levine.
1999.
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.
Proc. Natl. Acad. Sci. USA
96:3077-3080[Abstract/Free Full Text].
|
| 46.
|
Tomoda, K.,
Y. Kubota, and J.-Y. Kato.
1999.
Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1.
Nature
398:160-165[CrossRef][Medline].
|
| 47.
|
Wen, W.,
J. L. Meinkoth,
R. Y. Tsien, and S. S. Taylor.
1995.
Identification of a signal for rapid export of proteins from the nucleus.
Cell
82:463-473[CrossRef][Medline].
|
| 48.
|
Whitlock, J. P., and D. R. Galeazzi.
1984.
2,3,7,8-Tetrachlorodibenzo-p-dioxin receptors in wild type and variant mouse hepatoma cells. Nuclear location and strength of nuclear binding.
J. Biol. Chem.
259:980-985[Abstract/Free Full Text].
|
Molecular and Cellular Biology, August 2000, p. 6095-6104, Vol. 20, No. 16
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Nair, S., Kekatpure, V. D., Judson, B. L., Rifkind, A. B., Granstein, R. D., Boyle, J. O., Subbaramaiah, K., Guttenplan, J. B., Dannenberg, A. J.
(2009). UVR Exposure Sensitizes Keratinocytes to DNA Adduct Formation. Cancer Prevention Research
2: 895-902
[Abstract]
[Full Text]
-
Hughes, D., Guttenplan, J. B., Marcus, C. B., Subbaramaiah, K., Dannenberg, A. J.
(2008). Heat Shock Protein 90 Inhibitors Suppress Aryl Hydrocarbon Receptor-Mediated Activation of CYP1A1 and CYP1B1 Transcription and DNA Adduct Formation. Cancer Prevention Research
1: 485-493
[Abstract]
[Full Text]
-
Romero, N. M., Irisarri, M., Roth, P., Cauerhff, A., Samakovlis, C., Wappner, P.
(2008). Regulation of the Drosophila Hypoxia-Inducible Factor {alpha} Sima by CRM1-Dependent Nuclear Export. Mol. Cell. Biol.
28: 3410-3423
[Abstract]
[Full Text]
-
Monteiro, P., Gilot, D., Le Ferrec, E., Rauch, C., Lagadic-Gossmann, D., Fardel, O.
(2008). Dioxin-Mediated Up-Regulation of Aryl Hydrocarbon Receptor Target Genes Is Dependent on the Calcium/Calmodulin/CaMKI{alpha} Pathway. Mol. Pharmacol.
73: 769-777
[Abstract]
[Full Text]
-
Oesch-Bartlomowicz, B., Huelster, A., Wiss, O., Antoniou-Lipfert, P., Dietrich, C., Arand, M., Weiss, C., Bockamp, E., Oesch, F.
(2005). Aryl hydrocarbon receptor activation by cAMP vs. dioxin: Divergent signaling pathways. Proc. Natl. Acad. Sci. USA
102: 9218-9223
[Abstract]
[Full Text]
-
Lees, M. J., Peet, D. J., Whitelaw, M. L.
(2003). Defining the Role for XAP2 in Stabilization of the Dioxin Receptor. J. Biol. Chem.
278: 35878-35888
[Abstract]
[Full Text]
-
Degawa, M., Namiki, M., Yoshimoto, N., Makino, M., Iwamoto, M., Nemoto, K., Hashimoto, Y.
(2003). Constitutive Expression of Cytochrome P450 Genes in Newly Established Rat Hepatic Cell Lines. J Biochem
133: 825-831
[Abstract]
[Full Text]
-
Wormke, M., Stoner, M., Saville, B., Walker, K., Abdelrahim, M., Burghardt, R., Safe, S.
(2003). The Aryl Hydrocarbon Receptor Mediates Degradation of Estrogen Receptor {alpha} through Activation of Proteasomes. Mol. Cell. Biol.
23: 1843-1855
[Abstract]
[Full Text]
-
Song, Z., Pollenz, R. S.
(2003). Functional Analysis of Murine Aryl Hydrocarbon (AH) Receptors Defective in Nuclear Import: Impact on AH Receptor Degradation and Gene Regulation. Mol. Pharmacol.
63: 597-606
[Abstract]
[Full Text]
-
Eilers, A. L., Sundwall, E., Lin, M., Sullivan, A. A., Ayer, D. E.
(2002). A Novel Heterodimerization Domain, CRM1, and 14-3-3 Control Subcellular Localization of the MondoA-Mlx Heterocomplex. Mol. Cell. Biol.
22: 8514-8526
[Abstract]
[Full Text]
-
Berg, P., Pongratz, I.
(2002). Two Parallel Pathways Mediate Cytoplasmic Localization of the Dioxin (Aryl Hydrocarbon) Receptor. J. Biol. Chem.
277: 32310-32319
[Abstract]
[Full Text]
-
Andreasen, E. A., Tanguay, R. L., Peterson, R. E., Heideman, W.
(2002). Identification of a Critical Amino Acid in the Aryl Hydrocarbon Receptor. J. Biol. Chem.
277: 13210-13218
[Abstract]
[Full Text]
-
Berg, P., Pongratz, I.
(2001). Differential Usage of Nuclear Export Sequences Regulates Intracellular Localization of the Dioxin (Aryl Hydrocarbon) Receptor. J. Biol. Chem.
276: 43231-43238
[Abstract]
[Full Text]